Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine after a single dose (600 mg) of quinine sulphate was studied in eight extensive metabolizers (EM) and five poor metabolizers (PM). The mean elimination half-life of quinine in the PMs (10.2 +/- 1.6 (s.d.)h) was similar to that in the EMs (10.9 +/- 1.7 h). The oral clearance of quinine in the PM subjects was 0.092 +/- 0.021 l h-1 kg-1 and was not significantly different (P greater than 0.05) from that observed in the EM subjects (0.073 +/- 0.019 l h-1 kg-1). This suggests that even though quinine is extensively metabolized by oxidative biotransformation, this is carried out largely by P450 isoenzymes different from P450IID6 which oxidizes debrisoquine.
Wanwimolruk
S
S
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Chalcroft
S
S
D000328:Adult; D003647:Debrisoquin / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D010084:Oxidation-Reduction; D010641:Phenotype; D011803:Quinine / Q000097:blood / Q000493:pharmacokinetics*
D011803:Quinine; D003647:Debrisoquin